vTv Therapeutics (VTVT) EBIT Margin (2016 - 2025)
Historic EBIT Margin for vTv Therapeutics (VTVT) over the last 10 years, with Q4 2024 value amounting to 28776.47%.
- vTv Therapeutics' EBIT Margin changed N/A to 28776.47% in Q4 2024 from the same period last year, while for Sep 2025 it was 175382.35%, marking a year-over-year decrease of 1729828500.0%. This contributed to the annual value of 2377.58% for FY2024, which is N/A changed from last year.
- vTv Therapeutics' EBIT Margin amounted to 28776.47% in Q4 2024.
- vTv Therapeutics' EBIT Margin's 5-year high stood at 28.6% during Q4 2020, with a 5-year trough of 123433.33% in Q4 2021.
- Its 4-year average for EBIT Margin is 37016.52%, with a median of 34616.81% in 2024.
- As far as peak fluctuations go, vTv Therapeutics' EBIT Margin skyrocketed by 912857400bps in 2020, and later crashed by -1234619300bps in 2021.
- vTv Therapeutics' EBIT Margin (Quarter) stood at 28.6% in 2020, then tumbled by -431712bps to 123433.33% in 2021, then skyrocketed by 43bps to 70477.78% in 2022, then skyrocketed by 59bps to 28776.47% in 2024.
- Its last three reported values are 28776.47% in Q4 2024, 562.7% for Q1 2024, and 70477.78% during Q4 2022.